Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence

Prostate

Volumn 68, Issue 7, 2008, Pages 698-714

  D'Antonio, Jason M ^a   Ma, Changqing ^a,b   Monzon, Federico A ^a,c   Pflug, Beth R ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Androgen ablation; Androgen independent prostate cancer; Gene expression array; Survival

Indexed keywords

ANDROGEN; ANDROGEN METABOLIZING ENZYME; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOCHROME C; E1A PROTEIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELSOLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; MATRILYSIN; NUCLEAR RECEPTOR COACTIVATOR 2; NUCLEAR RECEPTOR COREPRESSOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SCATTER FACTOR RECEPTOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SONIC HEDGEHOG PROTEIN; STEROID RECEPTOR COACTIVATOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNINDEXED DRUG;

ANDROGEN ABLATION THERAPY; ANDROGEN METABOLISM; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR THERAPY; NEUROENDOCRINE DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENDOTHELIN-1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, ENDOTHELIN A; RECEPTORS, ANDROGEN;

EID: 43049131149     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20677     Document Type: Article

References (55)

1. American Cancer Society ISR. 2007 facts and figures, http://www.cancer. org/downloads/STT/CAFF2007PWSecured.pdf. 2007.
2. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
3. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. [Erratum appears in Prostate 1996 Jun;28(6):414]. Prostate 1996;28(4):251-265.
4. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26(2):263-273.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
6. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005;7(7):631-637.
7. Godara G, Cannon GW, Cannon GM Jr, Bies RR, Nelson JB, Pflug BR. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005;65(1):27-34.
8. Pflug BR, Reiter RE, Nelson JB. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 1999;40(4):269-273.
9. Ma C, Lyons-Weiler M, Liang W, LaFramboise W, Gilbertson JR, Becich MJ, Monzon FA. In vitro transcription amplification and labeling methods contribute to the variability of gene expression profiling with DNA microarrays. J Mol Diagn 2006;8(2):183-192.
10. Borcsok I, Schairer HU, Sommer U, Wakley GK, Schneider U, Geiger F, Niethard FU, Ziegler R, Kasperk CH. Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene. J Exp Med 1998;188(9):1563-1573.
11. Veldscholte J, Berrevoets CA, Mulder E. Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 1994;49(4-6):341-346.
12. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996;93(21): 11802-11807.
13. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. 1998;12(7):941-953.
14. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 2005;65(4):287-298.
15. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003;22(42):6570-6578.
16. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006;13(9):1197-1201.
17. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379(6565):557-560.
18. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60(18):5310-5317.
19. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6(5):517-527.
20. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88(7):2972-2982.
21. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10(4):303-360.
22. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 2006;12(14 Pt 1):4315-4330.
23. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. [See comment]. Science 2004;303(5659):848-851.
24. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64(19):6854-6857.
25. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 2006;119(9): 2071-2077.
26. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004;3:29.
27. Datta S, Datta MW. Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci 2006;63(4):435-448.
28. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006;231(1):20-27.
29. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 2001; 22(6):965-973.
30. Li F, Brattain MG. Role of the Survivin gene in pathophysiology. Am J Pathol 2006;169(1):1-11.
31. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM. The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2(12):1265-1275.
32. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(3 Suppl 1):132-138; discussion 138-139.
33. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007;120(4):719-733.
34. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007;67(7):3422-3430.
35. Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C. Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator. Cancer Res 2003;63(16):4888-4894.
36. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-2825.
37. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 2003;57(2):134-139.
38. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63(3):231-239.
39. Titus MA, Gregory CW, Ford OH III, ScheU MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11(12):4365-4371.
40. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006;68(1):2-8.
41. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract 1989;185(3):373-380.
42. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45(5): 586-592; discussion 592.
43. Lu S, Tsai SY, Tsai MJ. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 1999;140(11):5054-5059.
44. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142(11):4795-4805.
45. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17(9):1726-1737.
46. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 2006;13(1):151-167.
47. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 1994;91(11):4673-4677.
48. Adolf K, Wagner L, Bergh A, Stattin P, Ottosen P, Borre M, Birkenkamp-Demtroder K, Orntoft TF, Torring N. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007;67(5):472-484.
49. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007; 38(1):161-170.
50. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15(3):233-250.
51. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, Nelson JB, Pflug BR. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006;8(9):725-732.
52. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67(8):3818-3826.
53. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41(12 Pt 1):5070-5075.
54. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. [See comment]. Cancer J 2000; 6(4):220-233.
55. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23(1):1-9.